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Previous work has reported the important links between cellular bioenergetics and the
development of chronic kidney disease, highlighting the potential for targeting metabolic
functions to regulate disease progression. More recently, it has been shown that alterations
in fatty acid oxidation (FAO) can have an important impact on the progression of kidney
disease. In this work, we demonstrate that loss of miR-33, an important regulator of lipid
metabolism, can partially prevent the repression of FAO in fibrotic kidneys and reduce lipid
accumulation. These changes were associated with a dramatic reduction in the extent of
fibrosis induced in 2 mouse models of kidney disease. These effects were not related to
changes in circulating leukocytes because bone marrow transplants from miR-33–deficient
animals did not have a similar impact on disease progression. Most important, targeted
delivery of miR-33 peptide nucleic acid inhibitors to the kidney and other acidic
microenvironments was accomplished using pH low insertion peptides as a carrier. This
was effective at both increasing the expression of factors involved in FAO and reducing the
development of fibrosis. Together, these findings suggest that miR-33 may be an attractive
therapeutic target for the treatment of chronic kidney disease.
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Previous work has reported the important links between cellular bioenergetics and the development
of chronic kidney disease, highlighting the potential for targeting metabolic functions to regulate
disease progression. More recently, it has been shown that alterations in fatty acid oxidation (FAO)
can have an important impact on the progression of kidney disease. In this work, we demonstrate
that loss of miR-33, an important regulator of lipid metabolism, can partially prevent the repression
of FAO in fibrotic kidneys and reduce lipid accumulation. These changes were associated with a
dramatic reduction in the extent of fibrosis induced in 2 mouse models of kidney disease. These
effects were not related to changes in circulating leukocytes because bone marrow transplants
from miR-33–deficient animals did not have a similar impact on disease progression. Most
important, targeted delivery of miR-33 peptide nucleic acid inhibitors to the kidney and other
acidic microenvironments was accomplished using pH low insertion peptides as a carrier. This was
effective at both increasing the expression of factors involved in FAO and reducing the development
of fibrosis. Together, these findings suggest that miR-33 may be an attractive therapeutic target for
the treatment of chronic kidney disease.
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Introduction
Chronic kidney disease (CKD) is a widespread condition affecting over 30 million people in the United
States and about 10% of the population worldwide (1). The progression of this disease results in kidney failure, also known as end-stage renal disease (ESRD). ESRD causes nearly a million deaths each year globally,
and over 2 million people are currently receiving treatment. However, it is estimated that this is only a fraction of the people in need of treatment because of the expense and limited availability of currently available
therapies (chronic dialysis sessions or organ transplant), leading to over 1 million deaths each year (2).
Fibrosis is the final common pathway and histological manifestation of highly prevalent clinical conditions that lead to CKD, such as hypertension, nephroangiosclerosis, and diabetic nephropathy (DN).
It is characterized by the accumulation of collagen, activated myofibroblasts, and inflammatory cells, as
well as cell death, epithelial cell dedifferentiation, and loss of vascular supply in the kidney (3, 4). Renal
tubule cells have high baseline metabolic needs and rely mostly on fatty acids as their primary fuel source
to generate energy via mitochondrial oxidative phosphorylation (5). They have high levels of peroxisomal
proliferator–activated receptor-α (PPARα) and PPARγ coactivator-1α (PGC-1α) and a dense mitochondrial
network to support their metabolic and functional needs (6).
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Alterations in metabolic function are one of the biggest risk factors for CKD. Elevated blood
glucose levels are known to promote kidney dysfunction, and nearly one-third of patients with diabetes develop nephropathy (7). More recently, abnormal renal lipid accumulation has been linked
to the development of CKD and renal fibrosis (8). This has led to the prevailing concept that tubulo-interstitial fibrosis can be mediated or perpetuated by metabolic alterations, whereby reduced fatty
acid oxidation (FAO) plays a central role in promoting and prolonging fibrotic responses (9–13). The
use of different models of chronic kidney injury leading to renal fibrosis, including unilateral ureteral obstruction (UUO), folic acid–induced nephropathy (FAN), ischemia/reperfusion, or genetically
modified models, has allowed researchers to establish that this reduction is associated with decreased
expression of numerous FAO-related genes in renal tubular epithelial cells (TECs). Facing those metabolic constraints, TECs that survive injury respond by rearranging their cytoskeleton and acquiring a
less differentiated, mesenchymal phenotype (14).
Carnitine palmitoyltransferase 1a (CPT1a) is a mitochondrial enzyme central to the regulation of
FAO, through its role in the transport of long chain fatty acids from the cytoplasm into the mitochondria.
Reduction in the levels of this enzyme has been linked to an activation of the TGF-β axis in the context of
inflammatory response, leading to fibrogenesis through the inhibition of PPARα-dependent downstream
signaling (11). However, therapies based on the inhibition of TGF-β signaling have not yet been proved
valuable in human disease. Likewise, the use of fibrates as agonists of the PPARα family of receptors has
been curtailed in the clinic because of side effects involving renal function (15). Thus, it is important to
investigate new strategies that may provide a basis for therapeutic targets.
miRNAs are noncoding RNAs whose importance in pathophysiology has steadily grown over the
past decade. The ability of a single miRNA to inhibit a large number of mRNA targets can allow miRNAs to promote more robust responses by targeting multiple genes in the same or related pathways or to
elicit a broader cellular response by targeting genes in pathways that are generally not related. Although
this provides miRNAs the ability to regulate a wide variety of complex cellular responses, it also makes
it difficult to determine the specific mechanisms by which miRNAs mediate their effects. Recently, our
group was able to demonstrate that disruption of an individual miRNA/target interaction was sufficient
to mimic many of the effects of miRNA deficiency in vivo. Although this was the first work demonstrating the capacity of an individual miRNA/target interaction to mediate complex physiological phenotypes, the more moderate phenotype suggests other targets may also have been involved (16). Indeed, in
most cases multiple mRNA targets are likely involved in mediating the effects of an miRNA, and to add
a new level of complexity, the effects of a given miRNA can vary dramatically among tissues, cell types,
and physiological states because of differences in expression and target availability.
Several miRNAs have been related to the regulation of renal responses during fibrosis (17–19). Previous reports demonstrated that downregulation of miR-214 and miR-21, which have increased expression
in models of renal damage and are implicated in human renal pathology, is protective against renal fibrosis
(20–22). Alternatively, miR-29 expression is suppressed by TGF-β, promoting collagen expression and renal
fibrosis (23). However, the role of miRNAs in the regulation of renal fibrosis is still largely unexplored, and
recent work demonstrating the ability of miRNAs to regulate cellular bioenergetics suggests that these
novel regulators could constitute a pathogenic link between metabolism and fibrogenesis. We hypothesized
that miR-33, a major regulator of lipid metabolism, could represent an attractive candidate in this setting.
The miR-33 family of miRNAs are encoded within the sterol regulatory binding protein (SREBP)
genes. SREBP1 and SREBP2 are transcription factors responsible for the regulation of fatty acid and
cholesterol biosynthesis. miR-33a and miR-33b are cotranscribed along with their host genes and work
in a concerted manner by targeting genes involved in cholesterol efflux (ABCA1, ABCG1) (24, 25) and
FAO (CPT1a, CROT, HADHB) (26, 27). miR-33 is highly expressed in human and mouse kidneys (24,
25). Recent work has shown that miR-33 expression is increased in the serum of patients with diabetes
and even further elevated in patients with DN. Similarly, rodents with DN had higher levels of miR-33
both in blood and in renal tissue (28). In this work, we utilize miR-33–knockout mice (miR-33–/–) to investigate how genetic loss of miR-33 affects the development of kidney fibrosis. Our results indicate that
miR-33–deficient animals are protected from kidney fibrosis. This is likely due at least in part to reduced
renal lipid accumulation and increased expression of miR-33 target genes involved in FAO. We further
demonstrate that selective delivery of miR-33 peptide nucleic acid (PNA) inhibitors to the kidney, and
other acidic environments, using a pH low insertion peptide (pHLIP) carrier increased the expression of
insight.jci.org   https://doi.org/10.1172/jci.insight.131102
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Figure 1. Loss of miR-33 is protective against folic acid–induced renal fibrosis. (A) Renal fibrosis in WT and miR-33–/– mice was induced by i.p. injection
of folic acid (FA) (250 mg/kg body weight) (B). Representative microphotographs from 1 mouse per group and quantification (right) of Picrosirius red
staining of kidneys from WT and miR-33–/– mice under control (CT) conditions or following treatment with FA, indicating collagen deposition/accumulation
(n = 3–5). (C) Quantitative reverse transcription PCR (qRT-PCR) analysis of the expression of fibrosis-associated genes ASMA, FN1, and COL1A1 in kidneys
from WT and miR-33–/– mice under CT conditions or following treatment with FA (n = 5–6). (D) Representative images and quantification of Western blot
analysis of protein expression of fibrosis-associated genes: α-SMA, FN1, and COLIII in kidneys from WT and miR-33–/– mice under CT conditions (top) or
following treatment with FA (bottom). Relative protein levels were determined by band densitometry and are expressed in AU after correction for loading
CT GAPDH (n = 5). (E) Quantification of levels of BUN (left) and creatinine (right) in plasma samples of WT and miR-33–/– mice under CT conditions or
following treatment with FA (n = 5–7). All statistical significance was determined using nonparametric 2-tailed Mann-Whitney U test. Data represent the
mean ± SEM and *P < 0.05 comparing miR-33–/– with WT mice under the same conditions. Scale bar: 20 μm.

enzymes involved in FAO. Similar to what we observed in miR-33–/– mice, this treatment was effective in
reducing kidney fibrosis and inducing factors related to kidney damage. This approach may represent a
novel therapeutic avenue for the treatment of kidney disease.

Results
Loss of miR-33 protects mice against kidney fibrosis. We sought to determine whether miR-33 may play a direct
role in promoting the development of kidney dysfunction using 2 common models of kidney fibrosis, FAN
and UUO. Seven days after intraperitoneal (i.p.) injection of folic acid (Figure 1A), mice deficient in miR-33
showed a dramatic reduction in the development of kidney fibrosis compared with WT mice. Histological
analysis revealed that miR-33–/– mice had reduced accumulation of collagen as visualized by Sirius red staining (Figure 1B). The induction of fibrosis-associated markers (α–smooth muscle actin [α-SMA], fibronectin
[FN1], and collagen) in response to folic acid was also reduced in miR-33–/– mice at both the mRNA (Figure
1C) and protein levels (Figure 1D). Furthermore, common parameters indicative of kidney function, blood
urea nitrogen (BUN) and creatinine, were increased in animals injected with folic acid while this response
was blunted in miR-33–/– animals (Figure 1E). Notably, miR-33 and Srebp2 expression were not found to be
significantly altered in response to FAN (Supplemental Figure 1, A and B; supplemental material available
online with this article; https://doi.org/10.1172/jci.insight.131102DS1), suggesting that suppression of
basal miR-33 expression was sufficient to protect against folic acid–induced kidney fibrosis.
Similar results were obtained in miR-33–/– and control animals using an independent model of renal dysfunction, UUO surgery (Figure 2A). In this model UUO surgery is performed only in 1 kidney, leaving the
contralateral kidney as a nonfibrotic control. Similar to the findings observed in the FAN model, expression
insight.jci.org   https://doi.org/10.1172/jci.insight.131102
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Figure 2. Renal fibrosis is reduced in miR-33–/– mice following UUO. (A) Kidney fibrosis was induced by UUO, in WT
and miR-33–/– mice. The contralateral kidney was used as a nonfibrotic CT. (B) qRT-PCR analysis of the expression of
fibrosis-associated genes ASMA, FN1, and COL1A1 in WT and miR-33–/– mice in CT kidneys or following UUO surgery
(n = 4–6). (C) Representative images and quantification of Western blot analysis of protein expression of fibrotic factors α-SMA, FN1, and COLIII in kidneys of WT and miR-33–/– mice in CT kidneys (top) or following UUO surgery (bottom).
Relative protein levels were determined by band densitometry and are expressed in AU after correction for loading CT
GAPDH (n = 5). (D) Quantification of levels of BUN (left) and creatinine (right) in plasma samples of WT and miR-33–/–
mice in CT kidneys or after 3 or 10 days of UUO surgery (n = 4–6). All statistical significance was determined using
nonparametric 2-tailed Mann-Whitney U test. Data represent the mean ± SEM and *P < 0.05 comparing miR-33–/– with
WT mice under the same conditions.

of miR-33 and Srebp2 was unaffected by UUO surgical procedure (Supplemental Figure 1, C and D). However, induction of fibrosis-associated genes was significantly reduced in miR-33–/– mice at both the mRNA
(Figure 2B) and protein levels compared with WT mice (Figure 2C). Despite the presence of a functional
contralateral kidney, we also observed a trend toward decreased plasma BUN in miR-33–/– mice both 3 and
10 days after UUO surgery, along with a significant decrease in creatinine after 3 days of UUO (Figure 2D).
Together these findings demonstrate that loss of miR-33 is protective against kidney fibrosis in rodents.
Protection against kidney fibrosis in miR-33–/– mice is not due to changes in circulating macrophages or other hematopoietic cells. Similar to what we observed with fibrotic genes, the induction of mediators of inflammatory response
in animals treated with folic acid was blunted in kidneys from miR-33–/– animals, compared with WT controls
(Figure 3A). Because miR-33 has been shown to play an important role in the development of other chronic
inflammatory conditions, such as atherosclerosis, and to regulate macrophage polarization (29), we investigated
whether the reduced inflammation and fibrosis of miR-33–/– mice was due to effects on macrophages or other
insight.jci.org   https://doi.org/10.1172/jci.insight.131102

4

RESEARCH ARTICLE

Figure 3. Protection from kidney fibrosis in miR-33–/– mice is not due to effects on circulating leukocytes. (A) qRT-PCR
analysis of the expression of inflammatory genes: IL6, IL1B, TNFA, and CD68 in WT and miR-33–/– mice under CT conditions or following treatment with FA (n = 6). (B) Representative microphotographs from 1 mouse per group and quantification of Picrosirius red staining of kidneys from WT mice reconstituted with BM from WT (WT → WT) or miR-33–/– mice
(miR-33–/– → WT) under CT conditions or following treatment with FA (n = 4); quantification is shown at the right. (C)
Quantification of levels of BUN (left) and creatinine (right) in plasma samples of WT mice reconstituted with BM from WT
and miR-33–/– mice under CT conditions or following treatment with FA (n = 4–6). (D) qRT-PCR analysis of the expression
of fibrosis-associated genes ASMA, FN1, and COL1A1 in kidneys from WT mice reconstituted with BM from WT and miR-33–/–
mice under CT conditions or following treatment with FA (n = 4–5). (E) Representative images and quantification of
Western blot analysis of protein expression of fibrosis-associated genes: α-SMA, FN1, and COLIII in kidneys from WT mice
reconstituted with BM from WT and miR-33–/– mice under CT conditions or following treatment with FA. Relative protein
levels were determined by band densitometry and are expressed in AU after correction for loading CT GAPDH (n = 3). All
statistical significance was determined using nonparametric 2-tailed Mann-Whitney U test. Data represent the mean ±
SEM and *P < 0.05 comparing WT mice reconstituted with BM from miR-33–/– mice with animals reconstituted with WT
BM, under the same conditions. Scale bar: 20 μm.

inflammatory cells. To this end, we performed bone marrow transplant (BMT) experiments in which lethally
irradiated WT animals were reconstituted with bone marrow (BM) from either WT or miR-33–/– mice. One
month after BMT, mice were injected with folic acid, and the extent of kidney fibrosis was determined after
7 days. In contrast with our previous observations in miR-33–/– mice, kidney sections from mice reconstituted
with miR-33–/– BM did not show any differences in the amount of Sirius red–positive staining of collagen fibers
compared to kidneys from mice reconstituted with BM from WT mice (Figure 3B). Similarly, circulating levels
of BUN and creatinine were not altered in mice transplanted with miR-33–/– BM (Figure 3C), nor was the induction of fibrosis-associated genes altered (Figure 3D). Although the protein levels of fibronectin were reduced in
miR-33–/– BMT animals, other fibrotic markers, such as collagen and α-SMA, were unaffected (Figure 3E). These
findings indicate that the impact of miR-33 on kidney fibrosis is not due to effects on BM-derived macrophages
or other precursor hematopoietic cells and thus likely related to a localized effect within the kidney.
insight.jci.org   https://doi.org/10.1172/jci.insight.131102
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Figure 4. Loss of miR-33 increases FAO and reduces renal lipid accumulation. (A and B) Quantification of triglyceride (TAG) levels in total kidney tissue
from WT and miR-33–/– mice under CT conditions or following (A) FA treatment or (B) UUO surgery (n = 6–7). (C) Radiolabeled palmitate-derived CO2 was
determined after incubation of 14C-palmitate with kidney tissue from WT and miR-33–/– mice (n = 5–7). (D and E) Representative images and quantification
of Western blot analysis of protein expression of miR-33 target genes ABCA1 and CPT1A in the kidneys from WT and miR-33–/– mice under CT conditions or
following (D) treatment with FA or (E) UUO surgery. Relative protein levels were determined by band densitometry and are expressed in AU after correction
for loading CT GAPDH (n = 4–5). (F) Representative plots of Seahorse analysis of OCRs in primary renal TECs isolated from WT and miR-33–/– mice. Cells were
treated with palmitate-BSA FAO substrate. Oligomycin (1 μM), FCCP (3 μM), and a combination of antimycin A (1 μM) and rotenone (1 μM) (AA/Rot) were
injected sequentially at the indicated time points. Measurements were performed both under basal conditions and after treatment with the CPT1a inhibitor
etomoxir (Eto). Data are represented after normalization by protein amount. Bar graphs show the values of OCR associated with maximal respiratory status
(bottom) (n = 7–14 replicate wells; results are representative of at least 2 additional experiments with similar results). Statistical significance was determined using nonparametric 2-tailed Mann-Whitney U test (A, B, D, and E), unpaired 2-sided Student’s t test (C), and 1-way ANOVA with Bonferroni’s correction (F). Data represent the mean ± SEM and *P < 0.05 comparing tissues or cells from miR-33–/– with samples from WT mice under the same conditions.

Loss of miR-33 promotes FAO and reduces lipid accumulation in fibrotic kidneys. miR-33 is an important regulator of
FAO and cholesterol efflux. Notably, excessive lipid accumulation is known to be involved in kidney dysfunction
(30), and impairment in FAO in renal TECs has been associated with enhanced renal fibrosis (14). Hence, we
sought to determine whether alterations in lipid metabolism may be responsible for the protective effects of miR33 deficiency. Our data demonstrate that the amount of kidney triglycerides (TAGs) was significantly reduced in
miR-33–/– mice compared with WT mice after treatment with folic acid (Figure 4A) or following UUO surgery
(Figure 4B). We further demonstrate that FAO is enhanced in the kidneys of miR-33–/– mice, suggesting that the
reduced lipid accumulation we observed may be due to increased FAO (Figure 4C). These effects are likely due
at least in part to a direct action of miR-33 on CPT1a, a known target of miR-33 and critical regulator of FAO.
Western blot analysis demonstrated that CPT1a protein levels were markedly reduced in the kidneys of mice
insight.jci.org   https://doi.org/10.1172/jci.insight.131102
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Figure 5. miR-33 regulates FAO in human kidney tubule cells. (A) Representative plots of Seahorse analysis of OCRs in the human tubular cell line HKC-8
transfected with CT or miR-33 mimics (left). Cells were treated with palmitate-BSA FAO substrate. Measurements were performed both under basal
conditions and after treatment with the CPT1a inhibitor Eto to calculate the magnitude of several phases and parameters of mitochondrial respiration. Bar
graphs show the OCRs associated with maximal respiratory status (right) (n = 9 replicate wells). (B) qRT-PCR analysis of the expression of miR-33 target
genes involved in FAO, CPT1a, CROT, and HADHB, in HKC-8 cells transfected with CT or miR-33 mimics (n = 3). (C) Representative plots of Seahorse analysis of OCRs in HKC-8 cells transfected with CT or miR-33 inhibitors (left). Measurements were performed both under basal conditions and after treatment
with Eto to calculate the magnitude of several phases and parameters of mitochondrial respiration. Bar graphs show the OCRs associated with maximal
respiratory status (right) (n = 9 replicate wells). (D) qRT-PCR analysis of the expression of miR-33 target genes involved in FAO, CPT1a, CROT, and HADHB,
in HKC-8 cells transfected with CT or miR-33 inhibitors (n = 3). Statistical significance was determined using 1-way ANOVA with Bonferroni’s correction (A
and C) and nonparametric 2-tailed Mann-Whitney U test (B and D). All data represent the mean ± SEM and *P < 0.05 comparing HKC-8 cells transfected
with miR-33 mimics/inhibitors with cells transfected with CT constructs under the same conditions.

following folic acid treatment, and this repression was abrogated in miR-33–/– animals (Figure 4D). A similar
protective effect on blunting the suppression of CPT1a was observed in miR-33–/– mice following UUO surgery
(Figure 4E). To assess how miR-33 was mediating these effects, we first analyzed whether miR-33 is expressed
in renal TECs and regulates lipid metabolism. Previous data from our laboratory (31) and miRNA tissue atlas
database analysis (http://ccb-web.cs.uni-saarland.de/tissueatlas; Supplemental Figure 2A) show that miR-33
is expressed in mouse and human kidneys. Furthermore, analysis of the expression of miR-33 (miR-33a-5p in
humans) levels in 400 human primary cells (fanton.grs.riken.jp; Supplemental Figure 2B) revealed that primary
renal TECs isolated from 2 donors expressed high levels of miR-33 (only 9 and 13 human primary cell types had
higher miR-33 expression out of 400 tested). We further supported the expression of miR-33 by qRT-PCR (Ct =
23) in mouse primary renal TECs (Supplemental Figure 2C). Together these data indicate that miR-33 is present
in renal TECs. To determine how miR-33 expression influences mitochondria bioenergetics, we isolated primary
renal TECs from WT and miR-33–/– mice and assessed the mitochondrial respiratory capacity. The results show
that absence of miR-33 significantly enhanced the oxygen consumption rate (OCR). The effects of miR-33 deficiency on OCR were diminished in cells treated with the CPT1 inhibitor etomoxir, indicating that improved FAO
is largely responsible for these effects (Figure 4F). Overall, these data suggest that the reduced fibrosis we observed
in miR-33–deficient animals could be related to increased FAO and reduced lipid accumulation.
miR-33 regulates FAO in human renal TECs. We next sought to determine whether alterations in miR-33
expression could contribute to the development of kidney dysfunction in human cells. Using the HKC-8
insight.jci.org   https://doi.org/10.1172/jci.insight.131102
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Figure 6. pH low inducible peptides promote delivery of miR-33 inhibitors to the kidney. (A) Generation of anti–miR-33 PNA-conjugated pH low insertion
peptides (pHLIP) capable of delivering miR-33 inhibitors to acidic microenvironments. (B) Representative images of tissues from 1 mouse per group
injected with fluorescently labeled noninserting CT (pHLIP-750-5K) or targeted (pHLIP-750) constructs. (C) Representative images demonstrating uptake
of fluorescently labeled pHLIP constructs (pHLIP-A546) into primary renal TECs in vitro (shown in red). Costaining with lotus tetragonolobus lectin (LTL),
a marker for proximal tubules is shown in green. (D) Representative flow cytometry histograms showing fluorescence intensities in primary renal tubular
cells treated with CT (pHLIP-A546-5K), or targeted (pHLIP-A546) constructs. (E) Representative images and quantification of Western blot analysis of
protein expression of miR-33 targets CPT1A and CROT in the kidneys of mice treated with pHLIP scrambled CT (ScrpHLIP) or miR-33 inhibitory RNA constructs (anti–miR-33pHLIP) under CT conditions (top) or following treatment with FA (n = 10–11). Statistical significance was determined using nonparametric
2-tailed Mann-Whitney U test. All data represent the mean ± SEM and *P < 0.05 comparing mice treated with anti–miR-33pHLIP with animals treated with
ScrpHLIP under the same conditions. Scale bar: 20 μm.

human renal TEC line, we observed that the expression of miR-33 was not affected by treatment with
the profibrotic cytokine TGF-β (Supplemental Figure 3). We further demonstrate that treatment with
miR-33 mimics is sufficient to reduce mitochondrial respiration in human kidney cells and that these
effects are largely abolished by inhibition of FAO (etomoxir) (Figure 5A). Consistent with this, mRNA
expression levels of CPT1a and other miR-33 targets involved in FAO (CROT, HADHB) were reduced in
cells treated with miR-33 mimics (Figure 5B). Alternatively, treatment of HKC-8 cells with an inhibitor
of miR-33 improved mitochondrial respiration (Figure 5C) and increased mRNA expression of miR-33
targets involved in FAO (Figure 5D).
Treatment with miR-33 inhibitors targeted to the kidney. We next assessed whether inhibition of miR-33
could be an effective therapeutic strategy to prevent folic acid–induced kidney damage. miR-33 inhibitors have previously been used as a strategy for raising circulating HDL-cholesterol and reducing atherosclerotic plaque size in animal models (32). However, long-term treatment with miR-33 inhibitors or
genetic loss of miR-33 has been shown to result in detrimental unintended effects (33–35). As such, new
strategies to deliver inhibitors to atherosclerotic plaques or disrupt binding of specific miR-33 targets
could provide a more effective strategy. With this in mind, we have used the recently developed pHLIP,
insight.jci.org   https://doi.org/10.1172/jci.insight.131102

8

RESEARCH ARTICLE

Figure 7. Selective delivery of miR-33 inhibitors abrogated FA-induced renal fibrosis. (A) qRT-PCR analysis of the expression of fibrotic genes ASMA, FN1,
and COL1A1 in the kidneys of mice treated with ScrpHLIP or anti–miR-33pHLIP under CT conditions or following treatment with FA (n = 5). (B) qRT-PCR analysis
of the expression of inflammatory genes IL6, IL1B, TNFA, and COL1A1 in the kidneys of mice treated with ScrpHLIP or anti–miR-33pHLIP under CT conditions
or following treatment with FA (n = 6–7). (C) Representative images and quantification of Western blot analysis of protein expression of fibrosis-associated genes: α-SMA, FN1, and COLIII in the kidneys of mice treated with ScrpHLIP or anti–miR-33pHLIP under CT conditions or following treatment with FA (n =
10–11). (D) Representative microphotographs from mice treated with ScrpHLIP or anti–miR-33pHLIP after treatment with FA. (E) Quantification of levels of BUN
(left) and creatinine (right) in plasma samples of mice treated with ScrpHLIP or anti–miR-33pHLIP constructs under CT conditions or following treatment with
FA (n = 10–11). Statistical significance was determined using nonparametric 2-tailed Mann-Whitney U test. All data represent the mean ± SEM and *P <
0.05 comparing mice treated with anti–miR-33pHLIP with animals treated with ScrpHLIP under the same conditions. Scale bar: 100 μm.

which can deliver miRNA inhibitors, or other small oligonucleotides, selectively to areas of high acidity. This strategy has previously been employed to deliver miRNA inhibitors to the acidic microenvironment of tumors (36). The capacity of some portions of the mammalian nephron to secrete hydrogen
ions (37) theoretically provides an acidic microenvironment. This, together with the fact that original
reports have documented pHLIP renal accumulation (38), led us to develop anti–miR-33pHLIP PNA
constructs to inhibit miR-33 in the kidney (Figure 6A). Assessment of fluorescently labeled constructs
(TAMRA dye) confirmed that whereas standard delivery systems and noninserting control constructs
(pHLIP-750-K) convey inhibitors primarily to the liver, functional pHLIP constructs (pHLIP-750) have
extremely high uptake in the kidney (Figure 6B). Furthermore, we demonstrate uptake of fluorescent
pHLIP constructs in primary renal tubular cells by both fluorescent microscopy (Figure 6C) and flow
cytometry (Figure 6D and Supplemental Figure 4). Notably, we demonstrate that treatment with anti–
miR-33pHLIP constructs significantly increases protein levels of CPT1a as well as CROT, another miR-33
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target involved in FAO (Figure 6E). However, the expression of other known targets of miR-33 that
are involved in FAO and mitochondrial function, including PGC-1α and AMPK, were not found to be
altered in the kidneys of these mice (Supplemental Figure 5).
Importantly, we found that treatment with anti–miR-33pHLIP PNA constructs can substantially reduce
folic acid–induced kidney fibrosis. Similar to what we observed in miR-33–/– animals, treatment with anti–
miR-33pHLIP constructs reduced the induction of genes involved in both fibrosis (Figure 7A) and inflammation
(Figure 7B) in the kidney following folic acid treatment compared with scramble control PNAs (ScrpHLIP).
Similarly, the expression of proteins involved in fibrosis was significantly reduced in animals treated with
anti–miR-33pHLIP constructs (Figure 7C). We also performed histological staining of kidney sections from
these animals (Figure 7D) and assessed circulating factors associated with renal function, demonstrating a
significant decrease in circulating BUN and a similar trend for creatinine (Figure 7E).

Discussion
Although there are many causes of kidney dysfunction, alterations in metabolic function play an important
role in both the development and progression of CKD, including DN and tubulo-interstitial fibrosis, the
latter being the final common pathway for hypertensive renal disease and nephrosclerosis. Indeed, one of
the most common conditions in patients with diabetes mellitus is DN, which in turn is one of the largest
contributors to ESRD. In addition to ESRD, patients with DN are also much more likely to suffer from
events associated with cardiovascular disease (CVD) (39). Although very distinct, CKD and CVD are both
chronic inflammatory conditions associated with altered lipid metabolism (40). miR-33 is a well-known
mediator of lipid metabolism and a promising target for the treatment of CVD (41). In this work, we show
that loss of miR-33 protects against the development of kidney fibrosis, demonstrating the potential for
anti–miR-33 therapeutics that can target both CKD and CVD in patients suffering ESRD.
By using 2 models of renal injury (folic acid and UUO), we show that the genetic ablation of
miR-33 protects from the development of renal fibrosis. In addition, the presence of proinflammatory
markers typical of early fibrogenesis was also reduced. Inflammation contributes significantly to fibrogenesis (42), and miR-33 has been reported to influence macrophage polarization and shown to play an
important role in the development of other chronic inflammatory conditions, such as atherosclerosis.
Additional evidence suggests that miR-33 facilitates renal fibrosis in DN through the activation of the
NF-κB/TGF-β inflammation pathway (28). However, our data from BMT experiments demonstrate
that the protection from kidney fibrosis observed in miR-33–/– mice was not due to differences in circulating leukocytes, but rather to the local effect of miR-33 on TECs and other cells within the kidney.
Because our work focuses on the metabolic facet of renal fibrosis and the action of miR-33 in TECs, we
have not explored in depth the role of resident macrophages, which are important contributors to renal
fibrogenesis and would unlikely be replaced following BMT (43, 44). Also, this work has not addressed
whether miR-33 impinges on other pathogenic pathways related to CKD and fibrogenesis, such as epithelial-mesenchymal transition (45, 46).
Excessive lipid accumulation and impaired FAO have been repeatedly observed in several animal models
of acute and chronic renal injury, as well as in human patients (10, 11, 13, 47, 48). Increased lipid accumulation induces cellular lipotoxicity, contributing to fibrosis development (11). Although cell-specific overexpression of CD36 in TECs from mice leads to lipid accumulation, it is not sufficient to drive spontaneous
renal fibrogenesis (49). Therefore, it appears that defects in energy production have detrimental consequences
beyond mere lipid accumulation. miR-33 may also promote the accumulation of lipid droplets in the kidney
as described in other organs, thus contributing to kidney damage (33). The importance of impaired mitochondrial respiration as a forerunner of tubular damage is also underscored by the fact that mitochondrial substrate overload surpasses the catabolic capacity of mitochondrial β-oxidation and promotes tubular
injury (12, 50). A decrease in the expression of key metabolic transcription factors (PPARGC1A, PPARA, and
PPARG) in tubule cells (15) has been associated with the progression of fibrosis and CKD. Transgenic expression of PPARGC1A and PPARA caused protection from acute kidney injury or kidney fibrosis, indicating the
key role of metabolic pathways in maintaining kidney function and tubule health (10, 13, 51, 52). Furthermore, age-associated impairment of PPARα and FAO aggravates renal fibrosis (53). Consistent with this, the
pharmacological activation of PPARα by its agonist fenofibrate not only improved FAO but also significantly
reduced renal fibrosis development in the UUO and folic acid models. In addition, treatment with C75, a
synthetic compound that increases CPT1 activity and blocks fatty acid synthase, attenuated kidney fibrosis
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associated with FA administration (11). This molecule was also protective in the ischemia/reperfusion injury model, where stimulation of CPT1 activity by C75 recovered ATP depletion, improved renal function,
attenuated tissue injury, and inhibited proinflammatory cytokine production and neutrophil infiltration (54).
Nevertheless, neither fibrates nor C75 are currently accepted therapies for CKD either because of side effects
on renal function or lack of pharmaceutical development. As such, novel treatments aimed at preventing
CKD-associated metabolic alterations could provide a promising approach for the treatment of CKD.
miR-33 has been demonstrated to be a key regulator of FAO because of its ability to regulate key
enzymes in this process, including CPT1a. TECs rely exclusively on FAO and are unable to switch to
glycolysis in response to energy demand. Thus, pharmacological inhibition of CPT1 results in ATP
depletion, cell death, and dedifferentiation (11). In line with these observations, we observed that
FAO-associated mitochondrial respiration is increased in renal TECs from miR-33–/– animals. These
effects were greatly diminished in cells treated with etomoxir, indicating that these changes are largely due to the action of miR-33 on FAO. Other miR-33 targets involved in regulating mitochondrial
function and glucose metabolism could also contribute to the improved respiratory capacity of TECs
from miR-33–/– animals and the trend toward increased respiration even after inhibition of CPT1a. The
improved FAO in these cells was reflected in an increased capacity of kidney tissue from miR-33–/– mice
to oxidize 14C-palmitate. Consistent with this, the expression of CPT1a was increased in these mice
following renal injury, and the accumulation of lipids in the kidneys of these animals was dramatically
reduced. Furthermore, our results in human kidney cells are also strongly supportive of a potential role
for miR-33 in human kidney fibrosis. Studies of mitochondrial respiration and ATP production in these
cells demonstrated similar effects on FAO, exemplified by the changes in the expression of CPT1a, as
well as other miR-33 targets involved in FAO (CROT and HADHB). These findings suggest that treatment of human patients with inhibitors of miR-33 could increase the expression of genes involved in
FAO and reduce lipid accumulation, which could help protect against kidney dysfunction.
miRNAs have emerged as powerful regulators of fibrotic processes in the kidney (55, 56). Thus, Gomez
et al. identified 24 miRNAs that were commonly upregulated both in human CKD and in animal models
of kidney injury, suggesting a “fibrotic” miRNA signature in the kidney (18). miR-21 is arguably the first
miRNA shown to promote fibrosis by targeting PPARα-related metabolic pathways (22). Anti–miRNA-21
oligonucleotide-based therapy has also confirmed this finding in the murine model of Alport nephropathy
by reversing the associated mitochondrial dysfunction (17). Although the mechanism of action of miR214 in fibrosis is less well elucidated, it appears that miR-214 also targets metabolic responses (18). Earlier
work has suggested that miR-33 may play a role in the regulation of hepatic fibrosis, as it was reported that
inhibition of miR-33 reduces the mRNA expression of some fibrosis-associated factors in a nonalcoholic
steatohepatitis model (57). A profibrotic role for miR-33 has been also reported in cardiac fibrosis, as cardiac fibroblast-specific deficiency of miR-33 reduced cardiac fibrosis in response to pressure overload by
transverse aortic constriction. The proposed mechanism underlying this response was that deficiency of
miR-33 impaired cardiac fibroblast proliferation because of altered lipid raft cholesterol content (58, 59).
In the kidney, we demonstrate an important role for miR-33 in the regulation of FAO in TECs, which may
be relevant to explain its effects on fibrogenesis. However, it is likely that other known or predicted miR-33
targets may also be involved in helping promote these actions.
Because of their important role in the regulation of metabolic function and other pathways related to
fibrosis, miR-33 and other miRNAs could provide useful therapeutic targets for kidney disease. However,
the promiscuous nature of miRNAs increases the potential for unintended consequences, as has previously been observed with long-term treatment with inhibitors of miR-33 (33). Therefore, the ability to target
miRNA mimics and inhibitors to specific tissues could greatly enhance their therapeutic potential. In this
work, we used pHLIP technology to selectively deliver miR-33 inhibitors to the kidney, based on their
affinity for acidic microenvironments (36). We observed efficient uptake into the kidney and demonstrated
that selective delivery of miR-33 inhibitors to the kidney is sufficient to reduce folic acid–induced kidney
damage. These findings highlight the therapeutic potential of anti–miR-33pHLIP constructs for the treatment of CKD, while minimizing the potential risks of detrimental effects in other organs. Conceivably, a
similar approach can be used to selectively target other profibrotic miRNAs or deliver protective miRNAs
into the kidney. Hence, these findings highlight the potential for the selective targeting of kidney miRNAs
as a therapy for patients with CKD.
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Methods
Animals, BM transplantation, and models of renal fibrosis
Male C57BL/6 (WT) mice were originally purchased from The Jackson Laboratory (Bar Harbor, Maine,
USA) and kept under constant temperature and humidity in a controlled 12-hour light/12-hour dark
cycle. miR-33–/– mice were generated and characterized, and BMTs were performed as we have previously
described (35). Briefly, 8-week-old male mice were lethally irradiated twice 4 hours apart with a total dose
of 5.5 Gy (550 rads) before transplantation (X-RAD320, Precision X-Ray Inc.). BM was collected from
femurs of WT or miR-33–/– mice by flushing with sterile OptiMEM. Each recipient mouse was reconstituted with 2 × 106 BM cells through retroorbital injection. Four weeks after BMT, peripheral blood was
collected by retroorbital venous plexus puncture for PCR analysis of BM reconstitution.

Mouse models of kidney fibrosis
UUO. UUO surgery procedure was performed as previously described (60). Briefly, mice were anesthetized with isoflurane (3%–5% for induction and 1%–3% for maintenance). Mice were shaved on the left
side of the abdomen, a vertical incision was made through the skin with a scalpel, and the skin was
retracted. A second incision was made through the peritoneum to expose the kidney. The left ureter was
ligated twice 15 mm below the renal pelvis with surgical silk, and the ureter was then severed between
the 2 ligatures. Then, the ligated kidney was placed gently back into its correct anatomical position, and
sterile saline was added to replenish loss of fluid. The incisions were sutured and mice were individually
caged. Buprenorphine was used as an analgesic. A first dose was administered 30 minutes before surgery
and then every 12 hours for 72 hours, at a dose of 0.05 mg/kg subcutaneously. Mice were sacrificed by
CO2 overdose, and kidney and blood samples were harvested after perfusion with PBS at 3 and 10 days
after UUO. Contralateral kidneys were used as a nonfibrotic control for all experiments using this model.
FAN. In this model kidney fibrosis was induced by i.p. injection with 250 mg folic acid per kilogram
body weight dissolved in 0.3 M sodium bicarbonate (vehicle) as previously described (61). Control animals
received 0.3 mL of vehicle (i.p.). Mice were sacrificed by CO2 overdose, and kidneys and blood samples
were harvested after perfusion with PBS after 7 days of FA administration.

Histology, immunohistochemistry, and morphometric analyses
Kidneys were fixed in 10% neutral buffered formalin overnight, bisected sagittally, and submitted for standard
paraffin processing before sectioning at 5 μm. Sections were stained with H&E, or Sirius red, to evaluate extent
of renal injury and associated fibrosis. To quantify fibrosis, 20 randomly selected fields across 4 sections, evenly
distributed from pole to pole, limited to the cortex and avoiding preexisting perivascular and capsular collagen,
were captured with a ×20 objective using a polarizing filter and Leica DFC 495 digital camera connected to
a light microscope (Zeiss Axioskop). The area occupied by collagen was measured in each field using a computerized image analysis system (Leica Application Suite X, Leica Microsystems Inc.) and expressed in square
micrometers. The pathologist was blinded to genotype and treatment status of individual animals.

Cell culture
Human proximal TECs (HKC-8) were cultured in DMEM/F12 (1:1 vol/vol) supplemented with 15 mM
HEPES, 5% (vol/vol) fetal bovine serum, 1× insulin-transferrin-selenium, 0.5 μg/mL hydrocortisone, 50
U/mL penicillin, and 50 μg/mL streptomycin at 37°C and 5% CO2. HKC-8 cells were provided by Katalin
Susztak (Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA). HKC-8 cells were transfected with 40 nM miR-33 mimic or 60 nM miR-33
inhibitor using RNAiMAX (Thermo Fisher Scientific) for 8 hours, as described previously (62). All experimental control samples were treated with an equal concentration of a nontargeting control mimic sequence
or an inhibitor negative control sequence. Between 48 and 72 hours after transfection, cells were collected
for bioenergetic or mRNA analysis.

Isolation of primary kidney TECs
Kidneys from miR-33–/– and WT mice were collected after sacrifice and subjected to PBS perfusion (10
mL) followed by collagenase type II digestion (2 mg/mL, 10 mL). After digestion, the renal capsule and
medulla was removed. The rest of the kidney was minced and further digested in collagenase buffer for
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an additional 5 minutes at 37°C with rotation to release cells. Digested tissue and cell suspension were
passed through a 70-μm cell strainer, centrifuged at 50 g for 5 minutes, and washed in PBS for 2 rounds to
collect TECs. Isolated TECs were seeded onto a collagen-coated Petri dish and cultured in renal epithelial
cell medium (C-26130, PromoCell) supplemented with growth factors, including insulin, epinephrine, and
epidermal growth factor for TEC growth, as well as hydrocortisone for limiting growth of potential contaminating macrophages derived from the isolation (63).

Cellular bioenergetic analysis
FAO-associated OCR was studied using high-throughput extracellular flux analysis (Seahorse XFe96 and XFe24
analyzers, Agilent Technologies). Ex vivo, primary TECs isolated from WT or miR-33–/– mice were seeded onto
collagen-coated XFe96 cell culture microplates 24 hours before extracellular flux analysis. Growth medium was
replaced with substrate-limited medium (DMEM supplemented with 0.5 mM glucose and 1 mM glutamate)
the night before Seahorse assay. On the assay day, substrate-limited medium was replaced with Krebs-Henseleit
buffer assay medium supplemented with 0.2% carnitine for 1 hour at 37°C without CO2. The CPT1 inhibitor
etomoxir (MilliporeSigma) was added (4 μM) to the corresponding wells 15 minutes before starting the assay.
Finally, just before starting the assay, BSA or 200 mM palmitate-BSA FAO substrate was added.
Immediately, XF Cell Mito Stress Test was performed in a Seahorse XFe96 analyzer. FAO was assayed
through measurement of OCR changes in response to sequential injections of 4 compounds: oligomycin (1
μM, port A), FCCP (1 μM, port B), and antimycin/rotenone (1 μM, port C). After Seahorse assay, Hoechst
staining was performed for data normalization.
In vitro, 2 × 104 HKC-8 cells were transfected with miR-33 mimics, miR-33 inhibitors, or corresponding negative control sequences. Cells were then seeded in a Seahorse Bioscience XFe24 cell culture microplate, followed by the abovementioned preparation steps, and given 400 μM etomoxir treatment before
OCR measurements in response to oligomycin (1 μM, port A), FCCP (3 μM, port B), and antimycin/
rotenone (1 μM, port C) in an XFe24 analyzer. After the assay, protein was extracted from wells with 0.1%
NP-40–PBS solution and quantified with bicinchoninic acid protein assay (Thermo Fisher Scientific) for
data normalization. OCR and maximal respiration were determined as described previously (63, 64).

Kidney TAG measurement
Renal tissue lipids were sequentially extracted by the method of Bligh and Dyer (65) in the presence of
internal standards, including di-eicosanoyl–PC, di-tetradecanoyl–PE, and cholesteryl heptadecanoate.
Extracted renal lipids were resuspended in methanol/chloroform (4:1, by vol) to a dilution of about 20
pmol of lipid per microliter and analyzed by electrospray ionization mass spectrometry in the direct infusion mode at a flow rate of 3 μL/min using a Thermo Fisher Scientific Electron TSQ Quantum Ultra
instrument.

FAO
FAO was assayed as previously described (66). In brief, kidneys were removed from WT and miR-33–/– mice
and homogenized in 5 volumes of chilled STE buffer (pH 7.4, 0.25 M sucrose, 10 mM Tris-HCl, and 1
mM EDTA). The homogenate was immediately centrifuged and the pellet was resuspended and incubated
with a reaction mixture containing 0.5 mmol/L palmitate (conjugated to 7% BSA/[14C] palmitate at 0.4
μCi/mL) for 30 minutes. After this incubation period, the resuspended pellet-containing reaction mixture
was transferred to an Eppendorf tube, the cap of which housed a Whatman filter paper disc that had been
presoaked with 1 mol/L sodium hydroxide. The 14CO2 trapped in the reaction mixture medium was then
released by acidification of medium using 1 mol/L perchloric acid and gentle agitation of the tubes at
37°C for 1 hour. Radioactivity that had become adsorbed onto the filter disc was then quantified by liquid
scintillation counting in a beta counter.

Creatinine and BUN measurements
Briefly, creatinine was extracted from 20 μL of serum via a protein precipitation crash out using acetonitrile. The resulting extraction was then spiked with internal deuterated creatinine and analyzed via Ultra
High Pressure Liquid Chromatography System (Agilent Technologies) coupled in-line to a 4000 Q-Trap
mass spectrometer (AB Sciex). The extract was injected onto an Agilent Technologies column coupled to
an analytical Phenomenex SecurityGuard trap (C18, 4 × 3.0 mm). The column and trap were kept at 40°C.
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Bound creatinine was eluted at a flow rate of 500 μL/min using an acetonitrile/water mobile phase mixture
containing 0.1% formic acid. First quartile to (m/z 114) third quartile (m/z 44) and first quartile (m/z 117) to
third quartile (m/z 47) transitions were monitored for H3-creatinine (serum sample) and D3-creatinine (reference internal standard) abundance, respectively. Mass spectral data were collected and analyzed/quantified
using Analyst software (v.1.5). Standard curves of D3-creatinine were used to ensure linearity within the
creatinine measurements in the serum samples. Quantitative colorimetric determination of urea nitrogen in
plasma was performed using the diacetylmonoxime (DAM) method and measured at 520 nm on the Excel
Chemistry Analyzer (Stanbio Laboratory, Boerne, Texas, USA).

Western blot analysis
Kidneys were homogenized by manual disruption and the Bullet Blender Homogenizer and lysed in icecold buffer containing 50 mM Tris-HCl at pH 7.5, 0.1% SDS, 0.1% deoxycholic acid, 0.1 mM EDTA,
0.1 mM EGTA, 1% NP-40, 5.3 mM NaF, 1.5 mM NaP, 1 mM orthovanadate, and 1 mg/mL protease
inhibitor cocktail (Roche) and 0.25 mg/mL AEBSF (Roche). Lysates were sonicated and rotated at 4°C
for 1 hour before the insoluble material was removed by centrifugation at 12,000 g for 10 minutes. After
normalizing for equal protein concentration, cell lysates were resuspended in SDS sample buffer before
separation by SDS-PAGE. Following transfer of the proteins onto nitrocellulose membranes, the membranes were probed with the following antibodies: ABCA1 (Abcam; ab18180; 1:1000), CROT (Novus;
3144; 1:1000), CPT1a (Abnova; H00001374-DO1P; 1:1000), GAPDH (AF5718; 1:2000), α-SMA (MilliporeSigma; A5228; 1:2000), FN1 (MilliporeSigma; F3648; 1:1000), COLIII (Abcam; ab7778; 1:1000), and
VINCULIN (MilliporeSigma; V9131; 1:2000). Protein bands were visualized using the Odyssey Infrared
Imaging System (LI-COR Biotechnology), and densitometry was performed using ImageJ software (NIH).

RNA isolation and qRT-PCR
Total RNA from cells and tissue was isolated using TRIzol reagent (Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s protocol. For mRNA expression analysis, cDNA was synthesized
using iScript RT Supermix (Bio-Rad), following the manufacturer’s protocol. qRT-PCR analysis was
performed in duplicate using SsoFast EvaGreen Supermix (Bio-Rad) on an iCycler Real-Time Detection System (Eppendorf). The mRNA levels were normalized to 18S. Quantitative PCR primers are
listed in Supplemental Table 1.

PNA synthesis and pHLIP-PNA conjugate synthesis
pHLIP-PNA conjugations were performed as previously described (38). First, pHLIP-Cys (ADDQNPWRAYLDLLFPTDTLLLDLLWCG, CS Bio) was conjugated with Aldrithiol-2 (MilliporeSigma) to get
pHLIP-Cys(Pys). Aldrithiol-2 was added to peptide in dimethylformamide (DMF) to have a molar ratio of 1:1.
One hundred millimoles sodium phosphate and 150 mM NaCl buffer, pH 7.2 (saturated with argon), was added to the reaction mix (one-twentieth of total volume). Reaction mixture was incubated at room temperature
for 1 hour. pHLIP-Cys(Pys) was purified by reverse-phase HPLC (Zorbax SB-C18 columns, 9.4 × 250 mm, 5
μm; Agilent Technologies, the gradient consisting of a binary solvent system using water and acetonitrile with
0.05% trifluoroacetic acid [TFA] for 20%–70% over 40 minutes), lyophilized, and characterized by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry. Second, PNAs were added
to pHLIP-Cys(Pys) in DMSO (molar ratio 1:3) in the presence of 0.1 M ammonium bicarbonate, pH 8.8 (saturated with argon), one-fifth of total volume, and the reaction mixture was incubated overnight at 30°C. pHLIPPNA was purified by reverse-phase HPLC (Zorbax SB-C18 columns, 9.4 × 250 mm, 5 μm; Agilent Technologies, the gradient consisting of a binary solvent system using water and acetonitrile with 0.05% TFA for 5%–65%
over 40 minutes), lyophilized, and characterized by SELDI-TOF mass spectrometry.

pHLIP and K-pHLIP conjugation with Alexa Fluor 750 and Alexa Fluor 546 fluorescent dye
pHLIP (ACDDQNPWRAYLDLLFPTDTLLLDLLWA) and K-pHLIP (ACKKQNPWRAYLKLLFPTKTLLL KLLW) were conjugated at the N-terminus with Alexa Fluor 546– and Alexa Fluor 750–maleimide
(Life Technologies) in DMF at a ratio of 1:1 at room temperature for about 2 hours. One hundred millimoles
sodium phosphate and 150 mM NaCl buffer, pH 7.2 (saturated with argon), was added to the reaction mix
(one-twentieth of total volume). The reaction progress was monitored by the analytical reverse-phase HPLC
(Zorbax SB-C18 column, 4.6 × 250 mm, 5 μm; Agilent Technologies; the gradient consisting of a binary
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solvent system using water and acetonitrile with 0.05% TFA for 20%–75% over 30 minutes). More Alexa
Fluor–maleimide was added to the reaction mix, if it was needed. Constructs were purified by reverse-phase
HPLC (Zorbax SB-C18 columns, 9.4 × 250 mm, 5 μm; Agilent Technologies, the same gradient, over 40
minutes), lyophilized, and characterized by SELDI-TOF mass spectrometry. The concentrations of the constructs were determined by their absorbance using the following molar extinction coefficients: ε554 = 93,000
M/cm (for Alexa Fluor 546–pHLIPs), and ε753 = 290,000 M/cm (for Alexa Fluor 750–pHLIPs).

Assessment of pHLIP delivery
To determine the specificity of pHLIP delivery, animals were injected intravenously with pHLIP-750 or the
noninserting control peptide pHLIP-750-5K (4 nmol). Animals were sacrificed after 12 hours and uptake
was determined in different tissues by near-infrared fluorescence imaging, performed on an IVIS Spectrum
system (Caliper Life Science) with appropriate excitation (Ex) and emission (Em) filter sets (Ex/Em =
745/800 nm). Additionally, kidney sections were blocked with 10% donkey serum for 30 minutes and
stained with LTL (FL1321, Vector Laboratories) for 30 minutes at room temperature for localization of
renal epithelial cells (67). For flow cytometry analysis, kidneys were harvested 4 hours after injection with
pHLIP-546-5K or pHLIP-546, and cell dissociation was performed as described for isolation of kidney epithelial cells. A mixture of kidney cells was passed through a 70-μm cell strainer, and kidney epithelial cells
were stained with LTL (FL1321, Vector Laboratories). Flow cytometry was performed using a BD LSRII
(BD Biosciences), and data were analyzed using FlowJo software v8.7 (Tree Star, Inc.).

Anti–miR-33pHLIP treatment
ScrpHLIP and anti–miR-33pHLIP constructs were administered by intravenous injection at a dose of 1 mg/kg
body weight in PBS with 5% DMSO. Injections were performed 2 days before, the day of, 2 days after, and
5 days after administration of folic acid.

Statistics
Animal sample size for each study was chosen based on literature documentation of similar well-characterized experiments. The number of animals used in each study is listed in the figure legends. In vitro experiments were routinely repeated at least 3 times unless otherwise noted. No inclusion or exclusion criteria
were used. Data are expressed as average ± SEM. Statistical differences were measured using an unpaired
2-sided Student’s t test or 1-way ANOVA with Bonferroni’s correction for multiple comparisons. Normality
was checked using the Kolmogorov-Smirnov test. A nonparametric test (Mann-Whitney) was used when
data did not pass the normality test. P ≤ 0.05 was considered statistically significant. Data analysis was
performed using GraphPad Prism software version 7.

Study approval
All the experiments were approved by the Institutional Animal Care Use Committee of Yale University
School of Medicine.
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